Sequenom acquires assets of Ann Arbor-based SensiGen

Wednesday, January 28, 2009 | Source: Concentrate
Sequenom is taking a bite out of Ann Arbor's SensiGen and paying handsomely to do it.

The bio-tech firm is selling its AttoSense portfolio of tests along with a few other assets to Sequenom for $8.7 million. The two companies have worked together in the past, primarily on developing advanced gene-based molecular tests.

The AttoSense portfolio of tests includes analytically validated, ultra-sensitive and ultra-specific tests for detection and monitoring of human papillomavirus, which causes cervical, head and neck cancers, among other diseases.

SensiGen, a University of Michigan spin-off, has grown to more than half a dozen employees and a handful of contractors from the original two founders in the last four years. Some of its newest workers include two ex-Pfizer employees and the firm expects to hire more as soon as it closes its latest round of capital fundraising.

Source: Sequenom
Writer: Jon Zemke
Enjoy this story? Sign up for free solutions-based reporting in your inbox each week.

Related Tags

Biotechnology, Higher Education, Medical Research, University Of Michigan 

Recommended Content

Related Company

Sponsored By
Regions
Focus Areas
Copyright © Issue Media Group. All rights reserved.